Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBNP in real-world treatment of sepsis with cardiac dysfunction
ChiCTR2600124156Phase 4Recruiting
- Sponsor
- Guangxi Medical University Second Affiliated Hospital
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nesiritide in sepsis and heart failure (HF), sponsored by Guangxi Medical University Second Affiliated Hospital. Primary endpoints: Sequential Organ Failure Assessment (SOFA) score change and APACHE II score change. Started May 2026; status: recruiting.
02
Drugs
nesiritide
03
Conditions
sepsisheart failure (HF)
Beyond the preview
Go deeper on ChiCTR2600124156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124156.